Mobile health vehicles, commonly known as mobile clinics or health shuttles, provide preventive, diagnostic, and rehabilitative health services directly to clients in remote or underserved areas. Mobile health vehicles are specifically designed modular structures fitted with medical equipment that allows for examinations, treatments, and other healthcare services. They aim to take healthcare directly to the doorstep of communities who have limited access to hospitals or clinics. The growing preference for telehealth and remote patient monitoring during the COVID-19 pandemic has further accelerated the use of mobile health vehicles.
The Global Mobile Health Vehicle Market Size is estimated to be valued at US$ 281.9 Mn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
Growing adoption of telehealth and remote patient monitoring is one of the major opportunities driving the demand for mobile health vehicles. The COVID-19 pandemic has accelerated the shift towards telemedicine as people sought virtual care options to practice social distancing. Mobile health vehicles help expand telehealth access in rural areas by bringing basic healthcare and connectivity solutions directly to the patients. They can be utilized to conduct remote check-ups and consultations via video conferencing with doctors in hospitals. This trend of leveraging tele-technology for decentralized healthcare using mobile clinics is expected to continue post-pandemic, benefitting the mobile health vehicle market.
Porter's Analysis
Threat of new entrants: The high capital requirements for establishing mobile health vehicles act as a barrier for new entrants.
Bargaining power of buyers: Individual buyers have low bargaining power due to availability of substitute services. However, large institutional buyers have moderate power due to bulk purchasing.
Bargaining power of suppliers: The presence of numerous component suppliers gives buyers bargaining power over suppliers.
Threat of new substitutes: Emergence of telemedicine and home healthcare services pose a threat of substitution. Competitive rivalry: Intense competition exists among existing players to gain market share.
SWOT Analysis
Strengths: Mobile units increase access to care in remote areas. They offer curative and preventive services under one roof.
Weaknesses: High operational costs. Dependence on funding agencies raises sustainability concerns.
Opportunities: Growing geriatric population drives demand. Favorable regulatory framework promotes expansion.
Threats: Lack of awareness in rural areas. Shortage of trained medical staff impacts service quality.
Key Takeaways
The global mobile health vehicle market is expected to witness high growth. The global Mobile Health Vehicle Market is estimated to be valued at US$ 281.9 Mn in 2024 and is expected to exhibit a CAGR of 6.8% over the forecast period 2024-2031.
The market in North America holds the largest share due to growing focus on addressing healthcare inequities. Regional initiatives to expand services to underserved communities support market growth. Asia Pacific region is poised to be the fastest growing market for mobile health vehicles. Presence of large patient pool and increasing healthcare expenditure of countries like India and China will drive the market.
Key players operating in the mobile health vehicle market are Ecolab Inc., Novozymes A/S, Reckitt Benckiser Group PLC, Church & Dwight Co., Inc., The Clorox Company, Kikkoman Corporation, Spartan Chemical Company, Inc., Diversey, Inc., Johnson & Johnson, Danaher Corporation, Henkel AG & Co. KGaA, Procter & Gamble Co., DuPont de Nemours, Inc., Colgate-Palmolive Company, and Biokleen.
Get More Insights on This Topic: https://researchinsights24.weebly.com/blog/mobile-health-vehicle-market-is-estimated-to-witness-high-growth-owing-to-growing-telehealth-adoption
Explore More Information, Please Visit: https://coolbio.org/pharmacogenomics-a-promising-new-approach-to-personalized-medicine/
Know How Mobile Health Vehicle Market is Trending in Key Regions to Reach at Next Level in Coming Years?Mobile Health Vehicle Market size is projected to reach at a CAGR of 29.25% globally during forecast period 2021- 2027.Mobile Health Vehicles could be a customized care clinic that uses integrated technology to form care accessible to a bigger population.
in keeping with the planet Health Organization, they deploy mobile health vehicles to poor area unites that are discontinue from medical facilities.
The United Nations agency conjointly reports that the demand for these vehicles continues to grow thanks to varied blessings.
Mobile health care could be a response to a population living in remote and troublesome areas, wherever their communities are disconnected from thought services thanks to geographic and atmospheric condition.
whereas these cases will be reduced to mobile walkers with restricted scope for patient medical activities, a full-featured hospital could be a extremely complicated system that way exceeds a compact target system.
The Mobile health vehicles offer pressing care, preventive health screenings, and initiate chronic sickness management.Introspective research Reports has conducted associate degree intensive and intensive analysis of the planet Mobile Health Vehicle market.
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
